TABLE 2.
Demographic, clinical, and laboratory parameters of coronavirus disease 2019 (COVID‐19) patients at admission, as divided according to outcome status
| Variables | Asy (N = 10; 9.01%) | Sym (N = 63; 56.76%) | ICU (N = 29; 26.13%) | Dead (N = 9; 8.11%) | p‐Value |
|---|---|---|---|---|---|
| Age | 51.0 (45.7, 64.0) | 58.5 (48.0, 65.2) | 58.0 (50.0, 64.5) | 72.0 (58.0, 74.0) | 0.0406 |
| Ethnicity | |||||
| White‐European | 6 (60.0) | 56 (88.9) | 27 (93.1) | 8 (88.9) | N/A |
| Latin‐American | 3 (30.0) | 3 (4.8) | 2 (6.9) | 1 (11.1) | N/A |
| African | 1 (10.0) | 3 (4.8) | 0 (0.0) | 0 (0.0) | N/A |
| Asian‐Far East Asian | 0 (0.0) | 1 (1.6) | 0 (0.0) | 0 (0.0) | N/A |
| BMI | 27.0 (22.9, 31.9) | 28.1 (25.7, 36.7) | 27.7 (25.1, 31.0) | 28.4 (24.2, 29.4) | 0.9785 |
| Comorbidities | |||||
| CCI | 0.5 (0.0, 1.2) | 0.0 (0.0, 1.0) | 0.0 (0.0, 1.0) | 1.0 (0.0, 2.0) | 0.0802 |
| CCI‐age | 1.0 (0.0, 3.5) | 2.0 (1.0, 3.0) | 2.0 (1.0, 2.5) | 3.0 (3.0, 4.5) | 0.0261 |
| CCI (score) | |||||
| 0 | 5 (50.0) | 34 (54.0) | 21 (72.3) | 3 (34.0) | 0.1515 |
| 1 | 3 (30.0) | 15 (23.8) | 6 (20.7) | 2 (22.0) | 0.9455 |
| ≥2 | 2 (20.0) | 14 (22.2) | 2 (7.0) | 4 (44.0) | 0.0817 |
| Arterial hypertension | 2 (20.0) | 23 (37.0) | 11 (38.0) | 5 (56.0) | 0.4671 |
| CRP (mg/L) | 16.4 (2.1, 121.7) | 64.6 (29.6, 133.1) | 135.0 (40.9, 225.3) | 160.0 (33.0, 270.6) | 0.0209 |
| Laboratory parameters | |||||
| Critical‐Ill COVID‐19 | 68.9 (60.1, 96.9) | 94.1 (72.4, 111.1) | 107.1 (83.7, 122.8) | 115.5 (96.5, 142.5) | 0.0184 |
| IL‐6 (pg/ml) | 5.4 (3.3, 33.8) | 31.3 (21.1, 74.8) | 80.3 (17.3, 308.3) | 108.0 (46.9, 165.0) | 0.0011 |
| IL‐10 (pg/ml) | 4.5 (1.6, 6.0) | 6.0 (3.8, 9.0) | 8.2 (2.2, 20.0) | 19.1 (5.7, 62.8) | 0.0202 |
| HLA‐G5 (ng/ml) | 246.4 (159.6, 463.7) | 330.1 (230.7, 450.9) | 304.3 (153.4, 397.9) | 276.9 (122.3, 332.8) | 0.2284 |
| tT (nmol/L) | 4.3 (0.4, 11.7) | 2.9 (2.0, 5.6) | 0.94 (0.5, 1.5) | 0.4 (0.3, 2.9) | <0.0001 |
| E2 (pg/ml) | 28.3 (18.4, 38.1) | 34.9 (17.2, 43.2) | 31.0 (18.3, 43.7) | 40.4 (32.8, 63.9) | <0.0001 |
| SARS‐CoV‐2 IgG (AU/ml) | 17.7 (3.8, 82.7) | 16.8 (5.5, 66.7) | 94.4 (7.8, 128.5) | 10.1 (3.8, 102.5) | 0.0784 |
Continuous variables are presented as medians (interquartile range); categorical variables are presented as frequency (%). For each variable, one‐way ANOVA on ranks (Kruskal–Wallis test associated with Dunn's multiple comparison test) and Chi Square test were used for testing the difference among groups. Statistically significant p‐values are indicated in bold.
Abbreviations: Asy, asymptomatic, BMI, Body Mass Index; CCI, Charlson Comorbidity Index; CRP, C‐reactive protein; E2, 17β‐estradiol; ICU, intensive care unit; Sym, symptomatic; tT, total testosterone; WBC, white blood cells.
Critical‐Illness (Ill) COVID‐19 score was calculated as described in the methods.